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In their opening comments the panel members
were asked to comment on three questions: (1)
What disease frequency measures (e.g. inci-
dence, prevalence, incidence density or risk
(cumulative incidence)) can be used to compare
disease occurrence among the Nordic coun-
tries, if any; (2) Can you mention some exam-
ples (e.g. disease, countries); and (3) Can we or
should we make an effort to provide measure-
ments of disease frequency that can be com-
pared between countries?
After a good plenary discussion, it was gener-
ally recommended that we should bee able to
compare the disease frequency in the Nordic
countries but also among countries in Europe.
For some diseases, we can compare and trust
the disease free status (e.g. the list A diseases).
However, there are diseases present in the
Nordic countries where it is difficult to compare
the disease frequency (Salmonella and paratu-
berculosis). The problems are related to the sit-
uation in the countries (policy and history of
disease control programs) and not least the lack
of adequate diagnostic tests. One example of
the latter, discussed several times during the
meeting, is those for paratuberculosis. The
main problem with monitoring this disease is
that the diagnostic tests available are far from
perfect – both the sensitivity and specificity are
too low. 
The use of different monitoring and surveil-
lance systems can not be avoided because the
demographics and the disease control policy
may differ between countries. However, if the
monitoring and surveillance systems are well
defined and documented it should be possible to
compare disease frequencies among countries
even if the systems differ. A good and published
documentation is an advantage because it will
ensure that the MO&SS can be adapted to the
situation at hand in the respective country and
make it possible to use the information on dis-
ease occurrence in risk analysis and compari-
son among countries.
It is thus important that the national authorities
and the national veterinary laboratories follow
up on these important issues, as the Nordic
countries are and should remain a non-vacci-
nated area in the open European market for the
list A and B infectious diseases. The recom-
mendation is concerning: the diagnostic criteria
and documentation of disease combined with
MO&SS documentation.
